On September 27, 2013, FitLife Brands, Inc., formerly Bond Laboratories, Inc. (the "Company"), entered into an agreement (the "Agreement") with each holder of the Company's Series C Convertible Preferred Stock (the "Series C Preferred") to, collectively: (i) redeem one-half of the issued and outstanding shares of Series C Preferred for $10,000 per share, plus all accrued dividends thereon (the "Series C Redemption"), resulting in the payment of $670,084 to the holders of the Series C Preferred; (ii) convert all remaining shares of Series C Preferred and accrued dividends thereon into shares of the Company's common stock, par value $0.01 per share ("Common Stock"), at $0.25 per share, resulting in the issuance of a total of 2,680,337 shares Common Stock (the "Series C Conversion"); and (iii) exchange/cancel 2,500,000 warrants issued in connection with the original Series C Preferred financing for 624,998 shares of Common Stock (the "Series C Warrant Exchange"). A form of the Agreement is attached hereto as Exhibit 10.1.

The Series C Redemption, Series C Conversion and Series C Warrant Exchange mark the completion of the Company's planned recapitalization, as originally disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2013. The number of shares of Common Stock referenced in this Current Report on Form 8-K represent shares issued prior to the effective date of the one-for-ten reverse split of the Company's Common Stock consummated on September 30, 2013.

The 3,305,335 shares of Common Stock issued pursuant to the Series C Conversion and Series C Warrant Exchange were offered and sold in transactions exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(2) and/or 3(a)(9) thereof, and Rule 506 of Regulation D thereunder. Each of the holders of Series C Preferred represented that he was an "accredited investor" as defined in Regulation D.

See Item 8.01.

See Exhibit Index.